Five ways to beat German reimbursement
This article was originally published in Scrip
Executive Summary
Germany's new reimbursement system has tripped up a lot of companies since it arrived in January 2011. Boehringer struggled with its diabetes drug Tradjenta and, fearing it wouldn't get a premium price, decided against launching in Germany. Other firms have mis-timed dossier filings, chosen the wrong comparative treatments, or ignored the advice of advisors. And the problem is only going to bigger as the reimbursement authorities start retrospective assessments of drug classes. There may be a map for the German process but this only helps companies through the administrative process. To perform properly, firms need to tune-up their organizations and reshape internal attitudes.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.